| __timestamp | Merck & Co., Inc. | Vericel Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 13774000 |
| Thursday, January 1, 2015 | 10313000000 | 22479000 |
| Friday, January 1, 2016 | 9762000000 | 27388000 |
| Sunday, January 1, 2017 | 9830000000 | 35610000 |
| Monday, January 1, 2018 | 10102000000 | 49007000 |
| Tuesday, January 1, 2019 | 10615000000 | 61139000 |
| Wednesday, January 1, 2020 | 8955000000 | 68836000 |
| Friday, January 1, 2021 | 9634000000 | 97592000 |
| Saturday, January 1, 2022 | 10042000000 | 106903000 |
| Sunday, January 1, 2023 | 10504000000 | 120998000 |
Unleashing insights
In the world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Merck & Co., Inc. and Vericel Corporation have showcased contrasting trends in their SG&A efficiency.
Merck, a pharmaceutical giant, has seen its SG&A expenses fluctuate between 2014 and 2023, peaking in 2014 and 2019. Despite a slight dip in 2020, Merck's expenses have remained relatively stable, averaging around $10 billion annually. This stability reflects Merck's robust operational strategies and market presence.
In contrast, Vericel, a smaller biotech firm, has experienced a significant rise in SG&A expenses, growing nearly tenfold from 2014 to 2023. This increase highlights Vericel's aggressive expansion and investment in growth, as it seeks to establish a stronger foothold in the competitive biotech landscape.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Breaking Down SG&A Expenses: argenx SE vs Vericel Corporation
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Vericel Corporation
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Vericel Corporation vs Wave Life Sciences Ltd. Trends and Insights